Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc. is advancing its therapeutic product candidates, specifically BX211 and BX011, which have demonstrated positive clinical outcomes that indicate significant potential in treating diabetic foot osteomyelitis and chronic pulmonary infections. The favorable trends observed in the Phase 2 trial results for BX211, coupled with the positive FDA feedback for BX011's advancement into a Phase 2a study, suggest a pathway for enhanced market penetration and expansion into additional therapeutic indications. Furthermore, the potential for broadening valuation metrics internationally, alongside ongoing dialogue with the FDA, underscores an optimistic outlook for future growth and profitability in BiomX's innovative treatment solutions.

Bears say

BiomX Inc faces a negative outlook primarily due to the results of its recent clinical trials, where key endpoints narrowly missed statistical significance, particularly the week 13 PAR, which could undermine investor confidence. Additionally, the company may struggle to secure sufficient funding necessary for advancing its drug pipeline, compounded by the potential of dilutive capital raises that would adversely affect existing shareholder equity. Furthermore, uncertainty remains regarding the commercial viability of its therapies, which adds to the overall risk profile and impacts market sentiment negatively.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.